Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma

Abstract

Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.

Rituximab therapy in malignant lymphoma

“…However, this study did not have the power to show a significant difference and the follow-up is extremely short. In another phase II study, R-CHOP produced a CR rate of 77% and a 2-year survival rate of 75% without severe infectious complications (Boue et al, 2006).…”

Phase 2 study of intrathecal, long‐acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus‐related non‐Hodgkin lymphoma

“…Therefore, the liposomal cytarabine schedule was different according to the systemic chemotherapeutic regimens used. Patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) received CHOP (cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone) with rituximab (R-CHOP) 34 or rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (R-CDE) 35 every 3 weeks; patients with plasmablastic lymphoma or primary effusion lymphoma (PEL) received the standard CHOP, 36 and patients with Burkitt subtype received the rituximab plus cyclophosphamide, oncovin, hydroxydaunomycin, high-dose methotrexate, ifosphamide, etoposide, high-dose cytarabine (R-CODOX-M/IVAC) regimen 37 or the Stanford regimen for Burkitt. 38 Liposomal cytarabine was administered every 3 weeks in patients who received R-CHOP, CHOP, or R-CDE up to 6 cycles and on Day 1 of R-CODOX-M up to 3 cycles or on Day 1 of the Stanford regimen up to 6 cycles.…”

“…Moreover, comparing our schedule with that previously used with methotrexate or cytarabine in the most important published studies, a significant reduction of intrathecal injection occurred with comparable side effects. 19,21,[34][35][36][37][38]52 These data are reported in Table 3. This is an important matter both for patients and physicians.…”

HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

“…Several clinical trials (17)(18)(19)(20)(21) and observational studies (22)(23)(24) with HIV-infected lymphoma cases treated with HAART reported survival outcomes comparable to general patients with lymphoma. However, a few studies directly compared HIV-infected and HIV-uninfected patients with lymphoma and found inconsistent results.…”